Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Vice President, Finance | December 06, 2019 | December 06, 2019 |
| Carisma Therapeutics Inc.EBIO · Entity 74418 | Chief Financial Officer | April 03, 2017 | April 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date December 06, 2019 · Filed December 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,867 |
Reported balance
After 2019-12-06 transaction · row 1
1 source rowRow 1 · 2019-12-06 · Grant · Acquired 12,867 · Balance 12,867 F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2029-12-05 | Direct | 16,400 |
Reported balance
After 2019-12-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-06 · Grant · Acquired 16,400 · Balance 16,400 F2: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F2: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Carisma Therapeutics Inc.
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2027-04-02 | Direct | 14,077 |
Reported balance
After 2017-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 14,077 · Balance 14,077 F1: 50% of the shares subject to such option shall vest on grant date with the remaining 50% of shares underlying the option to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the shares subject to such option shall vest on grant date with the remaining 50% of shares underlying the option to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000899243-19-028706 · doc4.xml · derivative · entry 2 MCCABE JOHN J · CIK 0001205535 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2029-12-05 F2 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantCommon Stock | 12,867 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028706 · doc4.xml · nonDerivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,867 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:33 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 24,600 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005276 · doc4.xml · derivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,600 Underlying: Common Stock · 24,600 shares Expires 2029-02-26 F1 · derivative.exercise_date: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 20:20 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 4,603 | $0.00 Strike: $15.45 | $0.00 |
DisclosureSEC source: 0000899243-18-007375 · doc4.xml · derivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,603 Underlying: Common Stock · 4,603 shares Expires 2028-03-13 F1 · derivative.exercise_date: This stock option award was issued pursuant to the resTORbio, Inc. 2018 Stock Option and Incentive Plan. 25% of the shares shall vest on March 13, 2019; and the remaining 75% shall vest in equal quarterly installments thereafter. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:13 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,077 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001485003-17-000027 · wf-form4_149142317579239.xml · derivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,077 Underlying: Common Stock · 14,077 shares Expires 2027-04-02 F1 · derivative.exercise_date: 50% of the shares subject to such option shall vest on grant date with the remaining 50% of shares underlying the option to vest on the first anniversary of the grant date. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:09 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | SaleCommon Stock | 1,399 | $2.10 | $2,937.90 |
DisclosureSEC source: 0001485003-17-000004 · wf-form4_148728297397095.xml · nonDerivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,930 F1 · shares: The shares of common stock underlying the restricted stock units reported as disposed herein were sold by the issuer in satisfaction of tax withholding obligations associated with the vesting of such units. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 16:48 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001485003-16-000170 · wf-form4_147457729746241.xml · derivative · entry 2 MCCABE JOHN J · CIK 0001205535 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-19 F2 · derivative.exercise_date: 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 16:48 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 6,664 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001485003-16-000170 · wf-form4_147457729746241.xml · derivative · entry 1 MCCABE JOHN J · CIK 0001205535 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 6,664 shares Expires 2026-02-24 F1 · derivative.exercise_date: On February 25, 2016, the reporting person was granted an option to purchase 20,000 shares of common stock. This option vests in installments based on the achievement of certain regulatory and business milestones. The Compensation Committee of the Company determined that one of these performance milestones was met, resulting in vesting of the option with respect to 6,664 shares. The option had previously vested with respect to 13,336 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.